COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19

Résumé en anglais

We investigated the association of SARS CoV-2 vaccination with COVID-19 severity in a longitudinal study of adult cancer patients with COVID-19. 1610 patients who were within 14 days of initial positive SARS CoV-2 test and had received recent anticancer treatment or had a history of stem cell transplant or CAR-T cell therapy were enrolled between 5/21/2020 and 2/1/2022. Patients were considered fully vaccinated if they were 2 weeks past their second dose of mRNA vaccine (BNT162b2 or mRNA-1273) or a single dose of adenovirus vector vaccine (Ad26.COV2.S) at the time of positive SARS CoV-2 test. We defined severe COVID-19 disease as hospitalization for COVID-19 or death within 30 days. Vaccinated patients were significantly less likely to develop severe disease compared to those who were unvaccinated (OR = 0.44, 95% CI 0.28-0.72, p = 0.0008). These results support COVID-19 vaccination among cancer patients receiving active immunosuppressive treatment.